US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.90

-0.4900-2.01%

Post-market: 23.900.00000.00%19:30 EDT

Volume:496.35K

Turnover:12.03M

Market Cap:1.58B

PE:-7.69

High:25.56

Open:24.73

Low:23.77

Close:24.39

52wk High:30.99

52wk Low:10.30

Shares:66.17M

Float Shares:52.30M

Volume Ratio:1.00

T/O Rate:0.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1097

EPS(LYR):-2.5230

ROE:-41.01%

ROA:-26.14%

PB:3.37

PE(LYR):-9.47

Loading ...

Overview Company News Filings

Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors

Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer

Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32

Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile

THOMSON REUTERS

Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc

THOMSON REUTERS

Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC

Bicara Therapeutics management to meet with Cantor

Bicara CEO Claire Mazumdar sells $300,000 common shares

Bicara Therapeutics Highlights Momentum in Earnings Call

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38

Bicara grants new CCO option for 282,240 shares at $22.58 each

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BCAX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":23.9,"timestamp":1787342400000,"preClose":24.39,"halted":0,"volume":496353,"hourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020090200902009102,"floatShares":52302133,"shares":66172934,"eps":-3.109661,"marketStatus":"Not Yet Opened","change":-0.49,"latestTime":"08-21 16:00:00 EDT","open":24.73,"high":25.555,"low":23.77,"amount":12029223.159954,"amplitude":0.073186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":24.39,"preHourTrading":{"tag":"盘前","latestPrice":24.39,"preClose":24.39,"latestTime":"08:45 EDT","volume":3,"amount":73.17,"timestamp":1787316356497,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0006487493527585,"impliedVol":0.4166,"impliedVolPercentile":0.604},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":52302133,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":1.0006487493527585,"shares":66172934,"dividePrice":0,"high":25.555,"amplitude":0.073186,"preClose":24.39,"low":23.77,"week52Low":10.295,"pbRate":"3.37","week52High":30.99,"institutionHeld":0,"latestPrice":23.9,"eps":-3.109661,"divideRate":0,"volume":496353,"delay":0,"ttmEps":-3.109661,"open":24.73,"prevYearClose":16.83,"prevWeekClose":24.28,"prevMonthClose":27.1,"prevQuarterClose":29.69,"fiveDayClose":24.28,"twentyDayClose":27.02,"sixtyDayClose":21.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3125,"buy":0.5,"hold":0.1875,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":16,"updateTime":1787112000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-08-21","current":-7.685725,"percent":0.592975,"low":-22.704836,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"high":-5.144536,"avg":-10.510848,"sd":4.129805,"marketCap":1613957860},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860}],"updateTime":1787524557045},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642111475","title":"Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642111475","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642111475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:06","pubTimestamp":1781121985,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics held its annual shareholder meeting on June 9, 2026.Shareholders backed the selection of Christopher Bowden, M.D. and Carolyn Ng, Ph.D. to serve as directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDLchfRx7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910709","title":"Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910709","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910709?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:57","pubTimestamp":1780401472,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Hold rating on Bicara Therapeutics Inc., with a price target of $18.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-hold-rating-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-hold-rating-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640495548","title":"Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640495548","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640495548?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:55","pubTimestamp":1780311337,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Bicara Therapeutics Inc., with a price target of $42.00. R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-bicara-keeps-12-month-price-target-unchanged-at-42-on-encouraging-ficerafusp-alfa-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-bicara-keeps-12-month-price-target-unchanged-at-42-on-encouraging-ficerafusp-alfa-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639551609","title":"Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2639551609","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639551609?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:03","pubTimestamp":1780142593,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics published an ASCO poster on ficerafusp alfa with pembrolizumab in first-line R/M HPV-negative HNSCC with PD-L1 CPS ≥1.Pooled analysis linked deep response  to longer DOR, PFS, OS versus PR <80%.Median DOR 31.6 months for deep response versus 8.2 months for PR <80%; hazard ratio 0.31 .Median PFS 36.9 months versus 10.9 months; hazard ratio 0.35 .Median OS not reached versus 33.6 months; hazard ratio 0.37 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260530:nNDL3tyXRr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638230985","title":"Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2638230985","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638230985?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:48","pubTimestamp":1779832126,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics CFO Ivan Hyep sold 9,200 common shares on May 21 at a weighted average USD 20.42.He also exercised stock options for 9,200 shares at USD 3.79 on the same day.Hyep held 145,355 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1kS7mH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638054970","title":"Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638054970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638054970?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:55","pubTimestamp":1779814516,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $30.00. In addition to Wedbush, Bicara Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638301545","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638301545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638301545?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:50","pubTimestamp":1779807036,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsor...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bicara-therapeutics-inc-bcax-abivax-sa-sponsored-adr-abvx-and-arcutis-biotherapeutics-arqt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bicara-therapeutics-inc-bcax-abivax-sa-sponsored-adr-abvx-and-arcutis-biotherapeutics-arqt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4137","LU0128526141.USD","AAVXF","HCSG","XLV","BCAX","ARQT","LABU","BK4581","LU0029874061.USD","XBI","BK4585","ABVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637345356","title":"Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637345356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637345356?lang=en_us&edition=fundamental","pubTime":"2026-05-23 00:01","pubTimestamp":1779465665,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637639323","title":"Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2637639323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637639323?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:47","pubTimestamp":1779407257,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On May 21, 2026, Bicara Therapeutics reported three-year follow-up data f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317357","title":"Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637317357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035731","title":"Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637035731?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352703","title":"Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352703","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352703?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:01","pubTimestamp":1779397317,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics reported three-year follow-up results from its Phase 1/1b study of ficerafusp alfa with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck cancer.The results were slated for presentation at the 2026 ASCO Annual Meeting, with the updated dataset pointing to durable responses and longer-term survival that the company attributed to TGF-β inhibition.The readout underpins the company’s ongoing FORTIFI-HN01 pivotal program using the selected weekly dose regimen in combination with pembrolizumab.Bicara also plans to start a separate study in the third quarter of 2026 to test a loading-dose regimen followed by less frequent maintenance dosing to support longer-term treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL49cbby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352019","title":"Bicara Therapeutics management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352019?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397225,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on May 26 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878696","title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878696","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878696?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:08","pubTimestamp":1779307736,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics CEO and director Claire Mazumdar cut her stake to 362,152 shares on May 18.The filing shows sales of 15,000 shares at weighted average prices of USD 19.96 and USD 20.35.She also acquired 15,000 shares at USD 3.79 through an option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL3wS0Wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817130","title":"Bicara Therapeutics Highlights Momentum in Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636817130?lang=en_us&edition=fundamental","pubTime":"2026-05-20 16:41","pubTimestamp":1779266518,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Bicara Therapeutics’ latest earnings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-highlights-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-highlights-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006760","title":"Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006760?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:19","pubTimestamp":1779149954,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Bicara Therapeutics’ latest earnings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-earnings-call-highlights-ficera-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-earnings-call-highlights-ficera-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800963","title":"Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800963","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800963?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:25","pubTimestamp":1779135911,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, president and COO, sold 12,500 shares of Bicara Therapeutics common stock on May 15 at a weighted average price of USD 20.29.He also exercised stock options for 8,000 shares at USD 3.79 on the same day.He ended the day with 191,641 shares of common stock beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL7sGTvB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278262","title":"Bicara grants new CCO option for 282,240 shares at $22.58 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278262","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278262?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:32","pubTimestamp":1778675578,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics granted Chief Commercial Officer Christopher Sarchi a non-qualified stock option for 282,240 shares, effective May 8, 2026.Exercise price set at USD 22.58 per share, matching Nasdaq closing price on May 8.Vesting set at 25% on first anniversary of start date, remaining shares in 12 equal quarterly installments, subject to continued service.Award made under Bicara 2026 Inducement Plan, adopted by board in January 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3j8VkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4139","BCAX","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635825447","title":"Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635825447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635825447?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA4FHRHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782729","title":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782729","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782729?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"BOSTON, May  13, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293981/0/en/Bicara-Therapeutics-Announces-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4108","LU0828238088.HKD","LU0359201612.USD","LU0509642566.USD","BK4563","BK4565","LU0456842615.SGD","SG9999011746.SGD","IE00BYQNZ168.SGD","LU0359202008.SGD","BK4509","BK4535","IE00BYTNYN87.SGD","BK4548","LU2039709279.SGD","BK4531","BK4526","LU1023057109.AUD","BK4552","BK4571","LU0269904917.USD","BK4139","01698","BCAX","TME","IE00B12V2V27.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":140,"code":"91000000","status":"200"}]}}